journal
MENU ▼
Read by QxMD icon Read
search

Rheumatology and Therapy

journal
https://www.readbyqxmd.com/read/27900570/concomitant-use-of-statins-in-tocilizumab-treated-patients-with-rheumatoid-arthritis-a-post-hoc-analysis
#1
Martin Soubrier, Jinglan Pei, Frédérick Durand, Lars Gullestad, Ani John
INTRODUCTION: Patients with rheumatoid arthritis (RA) have decreased survival because of increased cardiovascular risk compared with the general population, and treatment with tocilizumab (TCZ) has been shown to increase lipid levels; however, the relationship between lipids and cardiovascular risk is unknown. This post hoc analysis expanded on previously reported 24-week results by characterizing statin use and subsequent changes in lipid parameters in patients with RA treated with intravenous or subcutaneous TCZ (TCZ-IV or TCZ-SC) over 2 years of treatment...
November 29, 2016: Rheumatology and Therapy
https://www.readbyqxmd.com/read/27817152/patient-perceptions-and-preferences-of-two-etanercept-autoinjectors-for-rheumatoid-arthritis-findings-from-a-patient-survey-in-europe
#2
Kunal Thakur, Anna Biberger, Alexandra Handrich, Mourad Farouk Rezk
INTRODUCTION: Benepali(®) was the first etanercept (Enbrel(®)) biosimilar to be approved in the European Union. Both Benepali and Enbrel are available as autoinjector devices. In a recent survey, nurses from France, Germany, Italy, Spain, and the United Kingdom (UK) reported that their patients with rheumatoid arthritis (RA) would prefer the Benepali autoinjector compared to the Enbrel MYCLIC autoinjector. To determine whether patients' perceptions were similar to those of the nurses, this survey evaluated patients' perceptions and preferences of the Benepali autoinjector versus the Enbrel MYCLIC autoinjector in the same five European countries...
December 2016: Rheumatology and Therapy
https://www.readbyqxmd.com/read/27804088/first-real-world-insights-into-belimumab-use-and-outcomes-in-routine-clinical-care-of-systemic-lupus-erythematosus-in-germany-results-from-the-observe-germany-study
#3
Andreas Schwarting, Johann O Schroeder, Tobias Alexander, Marc Schmalzing, Christoph Fiehn, Christof Specker, Alessandra Perna, Constanze Cholmakow-Bodechtel, Volker B Koscielny, Heike Carnarius
OBSErve Germany was the first observational study of belimumab as add-on treatment for systemic lupus erythematosus (SLE) in routine clinical care in Germany, retrospectively collecting data from 102 SLE patients, 6 months before and after belimumab initiation. Most patients had moderate or severe SLE and several SLE manifestations. After 6 months of belimumab treatment, 78% of patients showed an improvement in overall disease activity of at least 20% in their physician's judgment and for 42% of patients the improvement was at least 50%...
December 2016: Rheumatology and Therapy
https://www.readbyqxmd.com/read/27761754/review-of-osteosarcoma-and-current-management
#4
REVIEW
Ryan A Durfee, Maryam Mohammed, Hue H Luu
Osteosarcoma is the most common primary malignancy of bone in children and young adults. This tumor has a very heterogeneous genetic profile and lacks any consistent unifying event that leads to the pathogenesis of osteosarcoma. In this review, some of the important genetic events involved in osteosarcoma will be highlighted. Additionally, the clinical diagnosis of osteosarcoma will be discussed, as well as contemporary chemotherapeutic and surgical management of this tumor. Finally, the review will discuss some of the novel approaches to treating this disease...
December 2016: Rheumatology and Therapy
https://www.readbyqxmd.com/read/27747587/an-update-on-treatment-and-management-of-pediatric-systemic-lupus-erythematosus
#5
REVIEW
Amit Thakral, Marisa S Klein-Gitelman
Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disorder in which 20 % of patients are diagnosed in childhood. Childhood-onset SLE is associated with higher morbidity and mortality than adult-onset SLE. The aims of disease management with early immunosuppression are to decrease disease activity and improve quality of life. A multidisciplinary approach is necessary due to the complexity of lupus in pediatric patients. It is important to provide patients with high quality of care and to instill ownership of their disease process from a young age to prepare them to manage this life-long illness...
December 2016: Rheumatology and Therapy
https://www.readbyqxmd.com/read/27747586/erratum-to-perceptions-and-preferences-of-two-etanercept-autoinjectors-for-rheumatoid-arthritis-a-new-european-union-approved-etanercept-biosimilar-benepali-%C3%A2-versus-etanercept-enbrel-%C3%A2-findings-from-a-nurse-survey-in-europe
#6
https://www.readbyqxmd.com/read/27747585/long-term-safety-and-efficacy-of-subcutaneously-administered-tocilizumab-for-adult-rheumatoid-arthritis-a-multicenter-phase-3b-long-term-extension-study
#7
Alan Kivitz, Thomas Wallace, Ewa Olech, Michael Borofsky, Jenny Devenport, Jinglan Pei, Margaret Michalska
INTRODUCTION: To assess the long-term safety and efficacy of subcutaneous tocilizumab (TCZ-SC) in US patients with rheumatoid arthritis (RA) who rolled over from the two global phase 3 studies, SUMMACTA (NCT01194414) and BREVACTA (NCT1232569), into this open-label, single-arm, phase 3b study. METHODS: Patients continued to receive TCZ-SC 162 mg weekly or every other week or switched from intravenous TCZ to TCZ-SC 162 mg qw for up to 84 weeks. The primary endpoint was the proportion of patients with serious adverse events (SAEs)...
December 2016: Rheumatology and Therapy
https://www.readbyqxmd.com/read/27747584/economic-evaluation-of-timely-versus-delayed-use-of-tumor-necrosis-factor-inhibitors-for-treatment-of-psoriatic-arthritis-in-the-us
#8
Vibeke Strand, Elaine Husni, Jenny Griffith, Zheng-Yi Zhou, James Signorovitch, Arijit Ganguli
INTRODUCTION: The present study aimed to evaluate clinical outcomes and costs associated with timely versus delayed use of tumor necrosis factor inhibitors (TNFis) among patients with moderately to severely active psoriatic arthritis (PsA) with and without moderate/severe psoriasis (Ps) from a US payer's perspective. METHODS: An economic model evaluated PsA patients initially treated with a TNFi (timely TNFi use) or apremilast (delayed TNFi use). Patients without joint (American College of Rheumatology 20%, [ACR20]) improvement either switched TNFis or initiated one...
December 2016: Rheumatology and Therapy
https://www.readbyqxmd.com/read/27747583/randomized-crossover-comparison-of-injection-site-pain-with-40%C3%A2-mg-0-4-or-0-8%C3%A2-ml-formulations-of-adalimumab-in-patients-with-rheumatoid-arthritis
#9
Peter Nash, Johan Vanhoof, Stephen Hall, Udayasankar Arulmani, Rita Tarzynski-Potempa, Kristina Unnebrink, Andrew N Payne, Alfred Cividino
INTRODUCTION: Adalimumab, an anti-tumor necrosis factor antibody, is currently available in a 40 mg/0.8 mL formulation. The objective of this analysis was to evaluate injection site-related pain, safety, and tolerability of a 40 mg/0.4 mL formulation of adalimumab that had fewer excipients, a smaller volume, and a delivery presentation with a smaller gauge needle, versus the current 40 mg/0.8 mL formulation in patients with rheumatoid arthritis (RA). METHODS: Two identically designed, phase 2, randomized, single-blind, two-period crossover studies were conducted in Belgium and the Czech Republic (Study 1) and Australia, Canada, and Germany (Study 2)...
December 2016: Rheumatology and Therapy
https://www.readbyqxmd.com/read/27747582/juvenile-idiopathic-arthritis-diagnosis-and-treatment
#10
REVIEW
Gabriella Giancane, Alessandro Consolaro, Stefano Lanni, Sergio Davì, Benedetta Schiappapietra, Angelo Ravelli
Juvenile idiopathic arthritis is a broad term that describes a clinically heterogeneous group of arthritides of unknown cause, which begin before 16 years of age. This term encompasses several disease categories, each of which has distinct presentation, clinical manifestations, and, presumably, genetic background and etiopathogenesis. Although none of the available drugs has curative potential, prognosis has greatly improved as a result of substantial progresses in disease management. The most important new development has been the introduction of the biologic medications, which constitute a valuable treatment option for patients who are resistant to conventional antirheumatic agents...
December 2016: Rheumatology and Therapy
https://www.readbyqxmd.com/read/27747581/network-meta-analysis-and-cost-per-responder-of-tumor-necrosis-factor-%C3%AE-and-interleukin-inhibitors-in-the-treatment-of-active-ankylosing-spondylitis
#11
Keith A Betts, Jenny Griffith, Yan Song, Manish Mittal, Avani Joshi, Eric Q Wu, Arijit Ganguli
INTRODUCTION: Biologic therapies have improved the clinical management of ankylosing spondylitis (AS). Few head-to-head studies have directly compared the efficacy of these agents. This study was conducted to indirectly compare the efficacy of biologic agents for treatment of active AS. METHODS: A targeted literature review was conducted to identify randomized clinical trials for adalimumab, infliximab, golimumab, certolizumab pegol, etanercept, and secukinumab for the treatment of active AS...
December 2016: Rheumatology and Therapy
https://www.readbyqxmd.com/read/27747580/erratum-to-secukinumab-a-new-treatment-option-for-psoriatic-arthritis
#12
Philip Mease, Iain B McInnes
No abstract text is available yet for this article.
December 2016: Rheumatology and Therapy
https://www.readbyqxmd.com/read/27747579/incidence-of-gastrointestinal-perforations-in-patients-with-rheumatoid-arthritis-treated-with-tocilizumab-from-clinical-trial-postmarketing-and-real-world-data-sources
#13
Sharareh Monemi, Erhan Berber, Khaled Sarsour, Jianmei Wang, Kathy Lampl, Kamal Bharucha, Attila Pethoe-Schramm
INTRODUCTION: The aim of this study was to use multiple data sources to update information on gastrointestinal perforations (GIPs) during tocilizumab (TCZ) treatment in patients with rheumatoid arthritis (RA). METHODS: Reporting rates of GIP events were estimated from three distinct patient data sets: a TCZ-IV RA clinical trial all-exposure population, a global TCZ postmarketing safety database population, and a US healthcare claims database population of patients with RA, including patients who received TCZ, anti-tumor necrosis factor (aTNF) agents, or abatacept...
December 2016: Rheumatology and Therapy
https://www.readbyqxmd.com/read/27747578/costs-of-drug-therapy-in-patients-with-ankylosing-spondylitis-in-brazil
#14
Marina Amaral de Ávila Machado, Felipe Ferre, Cristiano Soares de Moura, Alessandra Maciel Almeida, Eli Iola Gurgel Andrade, Mariângela Leal Cherchiglia, Francisco de Assis Acurcio
INTRODUCTION: The Brazilian Public Health System offers free-of-charge drug treatment for ankylosing spondylitis (AS) to all Brazilian citizens. We report here the first population-based cohort study on patients with AS in Brazil. The aim of this study was to evaluate the costs of the tumour necrosis factor (anti-TNF) blockers and disease-modifying antirheumatic drugs (DMARDs) that were used in the treatments of patients with AS in Brazil between March 2010 and September 2013. METHODS: A retrospective cohort study was performed using administrative databases...
December 2016: Rheumatology and Therapy
https://www.readbyqxmd.com/read/27747522/emerging-therapies-for-rheumatoid-arthritis
#15
Joachim R Kalden
Diverse strategies to develop novel treatments for rheumatoid arthritis which specifically target those patients who do not respond to available medications, including biologics, are currently being explored. New potential therapeutic approaches which may become available as part of standard therapeutic regimens include the propagation of regulatory T cells and-in the future-of regulatory B cells. New biologic disease-modifying antirheumatic drugs (b-DMARDs) against interleukin-17 and -6, granulocyte-macrophage colony-stimulating factor, and complement component 5 are now standard components of clinical treatment programs...
June 2016: Rheumatol Ther
https://www.readbyqxmd.com/read/27747521/the-burden-of-rheumatic-diseases-an-analysis-of-an-italian-administrative-database
#16
Sergio Iannazzo, Gianluca Furneri, Federica Demma, Chiara Distante, Simone Parisi, Veronica Berti, Enrico Fusaro
INTRODUCTION: Chronic inflammatory rheumatic diseases (RDs) trigger high costs for healthcare systems and society due to the disability and comorbidity associated with these disease entities. The aim of this study was to analyze patients with RD, assess the use of conventional synthetic and biologic therapies, and estimate the overall cost of treatment in Italy. METHODS: Administrative healthcare claims from the Piedmont region in Northwest Italy were reviewed to identify patients who received disease-modifying antirheumatic drugs (DMARDs) between 2007 and 2010...
June 2016: Rheumatology and Therapy
https://www.readbyqxmd.com/read/27747520/disease-control-health-resource-use-healthcare-costs-and-predictors-in-gout-patients-in-the-united-states-the-united-kingdom-germany-and-france-a-retrospective-analysis
#17
Robert Morlock, Pierre Chevalier, Laura Horne, Javier Nuevo, Chris Storgard, Lalitha Aiyer, Dionne M Hines, Xavier Ansolabehere, Fredrik Nyberg
INTRODUCTION: The present study aimed to assess disease control, health resource utilization (HRU), and healthcare costs, and their predictors in gout patients across the USA, UK, Germany, and France. METHODS: Data were extracted from the PharMetrics Plus (USA), Clinical Practice Research Datalink-Hospital Episode Statistics (UK), and Disease Analyzer databases (Germany and France) for adult gout patients over a 3-year period: 2009-2011 (all dates +1 year for France)...
June 2016: Rheumatology and Therapy
https://www.readbyqxmd.com/read/27747519/perceptions-and-preferences-of-two-etanercept-autoinjectors-for-rheumatoid-arthritis-a-new-european-union-approved-etanercept-biosimilar-benepali-%C3%A2-versus-etanercept-enbrel-%C3%A2-findings-from-a-nurse-survey-in-europe
#18
Kunal Thakur, Anna Biberger, Alexandra Handrich, Mourad Farouk Rezk
INTRODUCTION: Enbrel(®) (etanercept: manufactured by Immunex Corporation, Newbury Park, Thousand Oaks, CA 91320, USA) was the first biological disease-modifying anti-rheumatic drug approved for the treatment of rheumatoid arthritis (RA) in Europe. More recently, an etanercept biosimilar (Benepali(®): manufactured by Biogen Inc, Cambridge, MA 02124, USA) was approved in the European Union. The perceptions and preferences of the Benepali autoinjector versus Enbrel MYCLIC autoinjector were evaluated by nurses from Europe...
June 2016: Rheumatology and Therapy
https://www.readbyqxmd.com/read/27747518/secukinumab-a-new-treatment-option-for-psoriatic-arthritis
#19
REVIEW
Philip Mease, Iain B McInnes
INTRODUCTION: Psoriatic arthritis (PsA) is an immune-mediated chronic inflammatory arthropathy associated with impaired physical function and reduced quality of life. Biologic therapies that target tumor necrosis factor (anti-TNF) have significantly improved clinical outcomes. Partial, non- and transient responses remain common comprising significant unmet clinical need. New therapies with novel modes of action are urgently required. OBJECTIVES: The interleukin (IL)-17 pathway has recently been attributed a critical role in the pathogenesis of spondyloarthritides...
June 2016: Rheumatology and Therapy
https://www.readbyqxmd.com/read/27747517/comparative-efficacy-of-bisphosphonates-to-prevent-fracture-in-men-with-osteoporosis-a-systematic-review-with-network-meta-analyses
#20
Junwen Zhou, Tiansheng Wang, Xilan Zhao, Donald R Miller, Suodi Zhai
INTRODUCTION: Osteoporosis is an under-recognized problem threatening men. Bisphosphonates are the main treatment but their comparative efficacy is unclear for men with osteoporosis. Therefore, we performed this systematic review with network meta-analyses to summarize the evidence of comparative efficacy of bisphosphonates in men with osteoporosis. METHODS: We completed network meta-analyses with a frequentist model to compare the efficacy of different bisphosphonates...
June 2016: Rheumatology and Therapy
journal
journal
53766
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"